This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribeiro, A. C.
Right arrow Articles by Barahona, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribeiro, A. C.
Right arrow Articles by Barahona, I.

 Previous Article  |  Next Article 

Journal of Virology, January 2005, p. 823-833, Vol. 79, No. 2
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.2.823-833.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Functional Analysis of Vif Protein Shows Less Restriction of Human Immunodeficiency Virus Type 2 by APOBEC3G

Ana Clara Ribeiro,1,2 Alexandra Maia e Silva,2 Mariana Santa-Marta,1 Ana Pombo,3 José Moniz-Pereira,1 Joao Goncalves,1 and Isabel Barahona2*

URIA, Centro de Patogénese Molecular, Faculdade de Farmácia, Universidade de Lisboa, Lisbon,1 Instituto Superior de Ciências da Saúde-Sul, Quinta da Granja, Monte da Caparica, Caparica,2 Portugal, and Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom3

Received 4 February 2004/ Accepted 27 August 2004

Viral infectivity factor (Vif) is one of the human immunodeficiency virus (HIV) accessory proteins and is conserved in the primate lentivirus group. This protein is essential for viral replication in vivo and for productive infection of nonpermissive cells, such as peripheral blood mononuclear cells (PBMC). Vif counteracts an antiretroviral cellular factor in nonpermissive cells named CEM15/APOBEC3G. Although HIV type 1 (HIV-1) Vif protein (Vif1) can be functionally replaced by HIV-2 Vif protein (Vif2), its identity is very small. Most of the functional studies have been carried out with Vif1. Characterization of functional domains of Vif2 may elucidate its function, as well as differences between HIV-1 and HIV-2 infectivity. Our aim was to identify the permissivity of different cell lines for HIV-2 vif-minus viruses. By mutagenesis specific conserved motifs of HIV-2 Vif protein were analyzed, as well as in conserved motifs between Vif1 and Vif2 proteins. Vif2 mutants were examined for their stability, expression, and cellular localization in order to characterize essential domains of Vif2 proteins. Viral replication in various target cells (PBMC and H9, A3.01, U38, and Jurkat cells) and infectivity in single cycle assays in the presence of APOBEC3G were also analyzed. Our results of viral replication show that only PBMC have a nonpermissive phenotype in the absence of Vif2. Moreover, the HIV-1 vif-minus nonpermissive cell line H9 does not show a similar phenotype for vif-negative HIV-2. We also report a limited effect of APOBEC3G in a single-cycle infectivity assay, where only conserved domains between HIV-1 and HIV-2 Vif proteins influence viral infectivity. Taken together, these results allow us to speculate that viral inhibition by APOBEC3G is not the sole and most important determinant of antiviral activity against HIV-2.

* Corresponding author. Mailing address: Instituto Superior de Ciências da Saúde-Sul, Quinta da Granja, Monte da Caparica, 2829-511 Caparica, Portugal. Phone: 351-21-2946725/30/61. Fax: 351-21-2946768. E-mail: ibarahona{at}egasmoniz.edu.pt.

Journal of Virology, January 2005, p. 823-833, Vol. 79, No. 2
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.2.823-833.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Henriet, S., Mercenne, G., Bernacchi, S., Paillart, J.-C., Marquet, R. (2009). Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors. Microbiol. Mol. Biol. Rev. 73: 211-232 [Abstract] [Full Text]  
  • Saini, M., Potash, M. J. (2006). Novel Activities of Cyclophilin A and Cyclosporin A during HIV-1 Infection of Primary Lymphocytes and Macrophages. J. Immunol. 177: 443-449 [Abstract] [Full Text]  
  • Cullen, B. R. (2006). Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors. J. Virol. 80: 1067-1076 [Full Text]  
  • Mahieux, R., Suspene, R., Delebecque, F., Henry, M., Schwartz, O., Wain-Hobson, S., Vartanian, J.-P. (2005). Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 86: 2489-2494 [Abstract] [Full Text]  
  • Jeeninga, R. E., Jan, B., van der Linden, B., van den Berg, H., Berkhout, B. (2005). Construction of a Minimal HIV-1 Variant that Selectively Replicates in Leukemic Derived T-Cell Lines: Towards a New Virotherapy Approach. Cancer Res. 65: 3347-3355 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»